Nasopharyngeal microbiome of COVID-19 patients revealed a distinct bacterial profile in deceased and recovered individuals
- PMID: 36252893
- PMCID: PMC9568276
- DOI: 10.1016/j.micpath.2022.105829
Nasopharyngeal microbiome of COVID-19 patients revealed a distinct bacterial profile in deceased and recovered individuals
Abstract
The bacterial co-infections in SARS-CoV-2 patients remained the least explored subject of clinical manifestations that may also determine the disease severity. Nasopharyngeal microbial community structure within SARS-CoV-2 infected patients could reveal interesting microbiome dynamics that may influence the disease outcomes. Here, in this research study, we analyzed distinct nasopharyngeal microbiome profile in the deceased (n = 48) and recovered (n = 29) COVID-19 patients and compared it with control SARS-CoV-2 negative individuals (control) (n = 33). The nasal microbiome composition of the three groups varies significantly (PERMANOVA, p-value <0.001), where deceased patients showed higher species richness compared to the recovered and control groups. Pathogenic genera, including Corynebacterium (LDA score 5.51), Staphylococcus, Serratia, Klebsiella and their corresponding species were determined as biomarkers (p-value <0.05, LDA cutoff 4.0) in the deceased COVID-19 patients. Ochrobactrum (LDA score 5.79), and Burkholderia (LDA 5.29), were found in the recovered group which harbors ordinal bacteria (p-value <0.05, LDA-4.0) as biomarkers. Similarly, Pseudomonas (LDA score 6.19), and several healthy nasal cavity commensals including Veillonella, and Porphyromonas, were biomarkers for the control individuals. Healthy commensal bacteria may trigger the immune response and alter the viral infection susceptibility and thus, may play important role and possible recovery that needs to be further explored. This research finding provide vital information and have significant implications for understanding the microbial diversity of COVID-19 patients. However, additional studies are needed to address the microbiome-based therapeutics and diagnostics interventions.
Keywords: And SARS-CoV-2; Nasopharyngeal microbiome; Opportunistic pathogens.
Copyright © 2022. Published by Elsevier Ltd.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Professor Chaitanya G Joshi reports financial support was provided by Government of Gujarat Department of Science and Technology.
Figures






References
-
- Assessment R.R. 2021. Assessment of the Further Emergence and Potential Impact of the SARS-CoV-2 Omicron Variant of Concern in the Context of Ongoing Transmission of the Delta Variant of Concern in the EU/EEA, 18th Update.
-
- Chaudhari A.M., Joshi M., Kumar D., Patel A., Lokhande K.B., Krishnan A., Hanack K., Filipek S., Liepmann D., Renugopalakrishnan V., Paulmurugan R., Joshi C. Evaluation of immune evasion in SARS-CoV-2 Delta and Omicron variants. Comput. Struct. Biotechnol. J. 2022;20:4501–4516. doi: 10.1016/j.csbj.2022.08.010. - DOI - PMC - PubMed
-
- Liu J., Liu S., Zhang Z., Lee X., Wu W., Huang Z., Lei Z., Xu W., Chen D., Wu X., Guo Y., Peng L., Lin B., Chong Y., Mou X., Shi M., Lan P., Chen T., Zhao W., Gao Z. Association between the nasopharyngeal microbiome and metabolome in patients with COVID-19. Synth. Syst. Biotechnol. 2021;6:135–143. doi: 10.1016/j.synbio.2021.06.002. - DOI - PMC - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources